Blood plasma proteins and clotting factors

Blood plasma proteins and clotting factors constitute a diverse array of molecules essential for maintaining vascular integrity and physiological homeostasis (StatPearls [1.1.1, 1.3.4]). This group includes albumin, which is primarily responsible for maintaining oncotic pressure and transporting hormones and drugs; globulins, which facilitate immune defense and transport; and a series of coagulation factors (e.g., Factor X, Thrombin, Fibrinogen) that execute the coagulation cascade (MicrobeNotes [1.2.1], Wikipedia [1.2.2]). These proteins are predominantly synthesized in the liver and circulate in inactive forms until triggered by vascular injury or inflammatory signals (MedlinePlus [1.1.3], CSL Behring [1.3.1]). Dysregulation of these factors leads to significant clinical conditions, including bleeding disorders like hemophilia and von Willebrand disease, or thrombotic disorders such as deep vein thrombosis and stroke (StatPearls [1.3.4], OlgaM [1.3.2]). Consequently, they are the primary targets for a wide range of therapeutic agents, including anticoagulants (e.g., warfarin, rivaroxaban), thrombolytics (e.g., alteplase), and recombinant replacement factors (Catalyst University [1.3.5]).

Other names

Plasma proteinsCoagulation factorsBlood clotting factorsSerum proteinsBlood coagulation factors

Drugs targeting these proteins act by inhibiting specific coagulation factors (e.g., Factor Xa or Thrombin), antagonizing Vitamin K to prevent the gamma-carboxylation of factors II, VII, IX, and X, activating endogenous inhibitors like antithrombin III, or replacing deficient factors in patients with bleeding disorders.